SELLAS Life Sciences Q1 Earnings Beat and Phase 3 Trial Update
13 May 2026 · 14:26 UTC · CoinCentral RSS Feed · Original source
Read original at CoinCentral RSS Feed →
Summary
SELLAS Life Sciences reported Q1 adjusted loss per share of $0.05, beating analyst estimates of $0.07. Stock jumped 20.4% in after-hours trading. The Phase 3 REGAL trial of Galinpepimut-S in acute myeloid leukemia reached 78 of 80 events needed for final analysis. Net loss widened to $8.4 million for the quarter.
Why it matters
SELLAS Life Sciences operates in the traditional biotech/pharmaceutical sector with no known cryptocurrency exposure, blockchain integration, or digital asset holdings. Q1 earnings announcements and clinical trial updates for AML treatment candidates are relevant only to biotech sector investors. There exists no causal mechanism linking traditional pharma company earnings to Bitcoin or altcoin price movements. The negligible crypto_relevance (0.02) reflects complete sector separation. Any correlation would constitute coincidental market noise rather than fundamental impact.
Expected impact
This article covers SELLAS Life Sciences, a traditional biotech pharmaceutical company, reporting Q1 financial results and clinical trial progress. The content has no direct relevance to cryptocurrency markets. While published on CoinCentral, a cryptocurrency news outlet, the article addresses traditional pharmaceutical sector developments with no connection to digital asset valuations, blockchain technology, or crypto market dynamics.